Widespread global disruption in routine childhood immunization has had a global effect, leaving an additional
3.7 million children missing basic vaccinations compared to pre-COVID-19 pandemic numbers.1
As part of a longer interview on vaccine acceptance (available here), Dr Angus Thomson (Irimi Company, Lyon, France) discusses the global uptake of COVID-19 vaccination, the impact the COVID-19 pandemic has had on the gains made over the past decade in increasing immunization, and outbreaks that can be linked back to a drop in immunizations.
Interviews available in this series:
- How has the COVID-19 pandemic impacted routine immunization programs? (0:50)
Disclosures: Dr Angus Thomson is a consultant for UNICEF, and Sabin Vaccine Institute.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
- World Health Organisation. Immunization coverage. Available at: www.who.int/news-room/fact-sheets/detail/immunization-coverage (accessed 4 October 2022).
Share this Video
Related Videos In Vaccines
The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: Iza Ciglenecki, EASL 2023
Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key findings of the campaign and unanswered questions, are discussed by Dr Iza Ciglenecki […]
The Hecolin® vaccine in the prevention of hepatitis E: Iza Ciglenecki, EASL 2023
A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease, and what is […]
PHH-1V vaccine compared to BNT162b2 as a SARS-CoV-2 booster vaccine, phase IIb results: Patricia Muñoz García, ECCMID 2023
PHH-1V, a SARS-CoV-2 protein-based heterodimer vaccine was investigated in a phase IIb trial where the immunogenicity and safety of a heterologous booster with PHH-1V was assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration. We spoke with Prof. Patricia Muñoz García (Gregorio Marañón General University Hospital, Madrid, Spain) […]